Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
5.20
-0.36 (-6.47%)
At close: Apr 14, 2026, 4:00 PM EDT
5.20
0.00 (0.00%)
After-hours: Apr 14, 2026, 5:14 PM EDT
Zentalis Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
106
Market Cap
368.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 216.11M |
| REGENXBIO | 170.44M |
| Sutro Biopharma | 102.48M |
| Assembly Biosciences | 72.30M |
| XOMA Royalty | 52.15M |
| Armata Pharmaceuticals | 4.90M |
| Absci | 2.80M |
| vTv Therapeutics | 17.00K |
ZNTL News
- 4 days ago - What's Behind The Surge In Zentalis Stock? - Benzinga
- 5 days ago - Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - GlobeNewsWire
- 13 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 7 weeks ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - GlobeNewsWire